plenary

This week we answer a few questions: the first is from Patreon backer, Harry Hong, on Kaplan-Meier curves. The second is from a student at Mount Sinai Medical School who reached out with some ethical questions they had after the ASH annual meeting on the obligations and responsibilities of peer reviewers. Finally, we end the episode with an interview with Dr. Bishal Gyawali of Queens University in Kingston, Ontario, Canada on his new paper out today in the Journal of the National Comprehensive Cancer Network titled "Response Rates and Durations of Response for Biomarker-Based Cancer Drugs in Nonrandomized Versus Randomized Trials". 

Durations of Response: doi.org/10.6004/jnccn.2019.7345

Vinay's new book, Malignant: www.amazon.com/Malignant-Policy-…cer/dp/1421437635

Back us on Patreon! www.patreon.com/plenarysession

January 2020

2.31 Listener Questions, Responsibility of Reviewers, & Duration of Response with Dr. Bishal Gyawali

This week we discuss management of COVID-19 in the intensive care unit with Dr. Benjamin Singer, a pulmonary and critical care physician at Northwestern University. We discuss medications, PPE, ventilators, and more!

Back us on Patreon! www.patreon.com/plenarysession

March 2020

2.44 ICU Management of COVID-19 with Dr. Benjamin Singer

This week we discuss several recent articles on the novel coronavirus (SARS-CoV-2) and COVID-19, specifically Dr. Siddhartha Mukherjee's article on the history and science of humanity's history with viruses, Dr. Ezekiel Emanuel's essay on how to fairly allocate dwindling medical resources during this global pandemic, and Dr. John Ioannidis's article on the "evidence fiasco" that has been our response to COVID-19. We end the episode with a Classical Hematology Chat with Drs. Sven Olson and Joseph Shatzel.

Dr. Mukherjee's article: https://www.newyorker.com/magazine/2020/04/06/how-does-the-coronavirus-behave-inside-a-patient
Allocation of Medical Resources: doi.org/10.1056/NEJMsb2005114
Dr. Ioannidis's article: https://www.statnews.com/2020/03/17/a-fiasco-in-the-making-as-the-coronavirus-pandemic-takes-hold-we-are-making-decisions-without-reliable-data/

Back us on Patreon! www.patreon.com/plenarysession

April 2020

2.45 Viral Spread of SARS-CoV-2, Rationing Resources, "Evidence Fiasco", & Classical Hematology Chat

This week we have a far-reaching monologue on COVID-19 and how people are reacting to the public health recommendations concerning COVID-19 (such as cancelling conferences and school, maintaining 6+ feet of distance, wearing cloth masks). We end with an insightful interview with Dr. Venk Murthy on polygenic risk score and, at the end, a bit about how the world of science is failing to combat hype.

Back us on Patreon! www.patreon.com/plenarysession

2.46 Psychology Unearthed by COVID-19 Precautions & Polygenic Risk Score with Dr. Venk Murthy

This week we start with an in-depth monologue on various new developments surrounding COVID-19, specifically the new study in NEJM on the compassionate use of remdesivir as well as the CDC's advice for the general public to wear cloth masks. We end with an interview with Dr. Ameet Sarpatwari of Harvard Medical School on how to create a more effective pharmaceutical system, the CREATES Act of 2019, developing fair and equitable drugs to treat COVID-19, and how to create a just system that balances the need for innovation with the need for access. Dr. Ameet Sarpatwari is the Assistant Director of PORTAL.

Compassionate Use of Remdesivir: doi.org/10.1056/NEJMoa2007016
U.S. Gene Therapy Trials: doi.org/10.1001/jama.2019.22214
NIH Fair Pricing Condition: doi.org/10.7326/M19-2576

Back us on Patreon! www.patreon.com/plenarysession

2.47 Remdesivir, Cloth Masks, & Incentives for COVID-19 Drug Development with Dr. Ameet Sarpatwari

This week's episode is jam-packed with topics! We talk about the RECOVERY trial, the U.S. clinical trial infrastructure, event-free survival (EFS) and cost of care in acute myeloid leukemia, how long it takes to write papers in academic medicine, threats to public health officials, and the application to medicine of Dr. Raj Chetty's work in economics. Finally, we interview this week's special guest, Dr. Ian Tannock, on docetaxel, prostrate cancer, clinical trial appraisal, and his career in medicine.

RECOVERY: https://www.recoverytrial.net/
EFS in AML: doi.org/10.1182/bloodadvances.2019001150

Malignant audiobook: https://www.audible.com/pd/B08864KFHW/?source_code=AUDFPWS0223189MWT-BK-ACX0-195112&ref=acx_bty_BK_ACX0_195112_rh_us

Back us on Patreon! www.patreon.com/plenarysession

June 2020

2.57 RECOVERY, Clinical Trials in the US, EFS, Writing, Dr. Raj Chetty, & Dr. Ian Tannock

Dr Prasad currently serves as the Director of the Center for Biologics Evaluation and Resesarch (CBER) at the US FDA. The audio on this platform were posted before my FDA employment and do not necessarily represent the views of the FDA or the United States. This site will be inactive during my federal service.

A podcast on medicine, oncology, & health policy. 
Host: Vinay Prasad, MD MPH from University of California San Francisco.
Tweet your feedback to @Plenary_Session or e-mail plenarysessionpodcast@gmail.com

2.57 RECOVERY, Clinical Trials in the US, EFS, Writing, Dr. Raj Chetty, & Dr. Ian Tannock

Plenary Session - inactive due to federal service